The Medicare Advantage Rebound Will Be Paid for in Benefits

The Medicare Advantage relief rally is being read too generously.

Yes, the rate backdrop got better. On April 6, CMS said 2027 Medicare Advantage payments would rise 2.48% on average, and officials said insurers would also get about a 2.5% benefit from a change tied to risk assessment payments. The market heard one word: relief.

But the real margin repair is not coming from Washington suddenly deciding to be generous. It is coming from insurers making Medicare Advantage a skinnier product.

That is the part investors should watch.

The first scene was the stock reaction. Humana, UnitedHealth, and CVS jumped after the final rate notice because the January proposal had looked much tighter, and the final package meant more than $13 billion in additional payments to MA plans in 2027. After three years of ugly utilization pressure, that felt like oxygen.

The second scene was much less celebratory. By May 1, investors and industry experts were already warning that 2027 enrollees should expect fewer extras like dental, vision, transportation, meals, and gym memberships. Humana said outright it would have to adjust benefits to get back to a sustainable margin of at least 3%.

That tells you what this business is becoming.

For years, Medicare Advantage sold itself like a consumer product. The pitch was not just care coordination or managed risk. It was the bundle. A senior could compare plans and see the add-ons right there: the dental allowance, the hearing help, the rides, the fitness perk, the small conveniences that made the private plan feel like an upgrade from traditional Medicare.

Now the upgrade is getting repriced.

The cleanest way to understand the sector is this: Medicare Advantage is shifting from a perk-heavy acquisition business to a plan-design business.

That sounds subtle, but it changes where the money sits.

If the headline payment rate is not rich enough to absorb elevated medical use, insurers have to pull a different lever. They can trim supplemental benefits. They can exit weaker counties. They can reshape provider networks. They can lean harder on Star ratings, coding discipline, and operational control. In other words, they stop trying to win every senior and start trying to win the right senior at the right margin.

That is why the benefit cuts matter more than the rate headline.

They are not just a cost-saving measure. They are a selection tool.

Reuters reported that Humana derives about 80% of revenue from Medicare Advantage, versus roughly 33% for Aetna and 12% for UnitedHealthcare. That kind of exposure explains why Humana is more explicit. It has less room to pretend this is a temporary bump. If margins are not repaired in product design, they will not be repaired at all.

UnitedHealth’s own first-quarter numbers point in the same direction. UnitedHealthcare’s operating margin improved to 6.6% from 6.2%, helped by repricing across lines of business. But its Medicare Advantage membership declined by 965,000 in the quarter. That is not the picture of a company chasing raw volume. It is the picture of a company deciding that some membership is not worth the economics.

This is where many casual readers get the story wrong. They see better first-quarter earnings and assume the managed-care pain is ending because medical costs are finally calming down.

Maybe. But even the bullish read is cautious.

Reuters reported on May 13 that analysts still want to see a second clean quarter before declaring victory, and some of the recent relief may have been helped by one-off factors such as a weaker respiratory season and weather-related care delays. UnitedHealth’s CFO said April and May claims development would matter. That is a polite way of saying: do not build a full-year margin thesis on one spring quarter.

So if medical-cost stabilization is not yet fully bankable, what is bankable?

The answer is insurer behavior.

Management teams can control benefit design faster than they can control the epidemiology of aging members. They can redesign bids, narrow generosity, and push the product toward members who are less expensive to serve. Politically, that is awkward. Financially, it is rational.

The consequence is that Medicare Advantage may keep growing while becoming less plush.

That matters for three groups.

• For investors, the winners may be the plans with the best product-pricing discipline, not necessarily the broadest footprint or the loudest rebound narrative.
• For operators, Star ratings and bid execution start to matter more because every basis point of funding has to be protected somewhere else in the product.
• For members, the sticker price may still look manageable while more of the pain shifts into narrower extras and higher out-of-pocket tradeoffs.

The biggest misunderstanding in healthcare right now is that MA margins recover when CMS blinks.

No. They recover when insurers quietly rewrite what “advantage” means.

By open enrollment, seniors may discover that the business model fix was sitting in the benefits booklet all along.

That is not a temporary patch. It is the sector admitting that the easy version of Medicare Advantage is over.